Fluconazole should not be standard fungus prophylaxis for people with HIV -- new PHS/IDSA guidelines.
FLUCONAZOLE SHOULD NOT BE USED FOR ROUTINE HIV PROPHYLAXIS of the fungal infections candidiasis and cryptococcosis, the Public Health Service and the Infectious Diseases Society of America recommend in new guidelines for prevention of opportunistic infections. Pfizer's Diflucan (fluconazole) is approved for treatment of oropharyngeal and esophageal candidiasis and cryptococcal meningitis often related to HIV/AIDS; as prophylaxis for candidiasis in patients who undergo bone marrow transplantation who receive chemotherapy; and, most recently, for treatment of vaginal candidiasis ("The Pink Sheet" July 11, p. 8).
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth